Efficacy of sofosbuvir and ledipasvir in an HCV+ gastro-resected patient

C. Taibi, M. Tempestilli, A. D'Avolio, A. R. Garbuglia, A. De Nicolò, M. Montalbano, G. D'Offizi

Research output: Contribution to journalArticlepeer-review


What is known and objective: The second-generation direct-acting antivirals represented the first major turning point for the eradication of HCV infection in almost all settings of patients. However, no data were available on use in gastro-resected patients. Case description: We report on a gastrectomized patient with chronic hepatitis C infection. She was treated with sofosbuvir and ledipasvir (SOF/LDV) for 12 weeks, with measurement of blood levels of the drugs. She obtained sustained virological response at week 12 and 24 without dose adjustment. What is new and conclusion: This case report can provide information useful for clinical practice in this set of patients and can open new perspectives in evaluating actual SOF/LDV bioavailability.

Original languageEnglish
Pages (from-to)621-623
Number of pages3
JournalJournal of Clinical Pharmacy and Therapeutics
Issue number5
Publication statusPublished - Oct 1 2017


  • gastrectomy
  • hepatitis C virus
  • ledipasvir
  • pharmacokinetics
  • sofosbuvir

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Efficacy of sofosbuvir and ledipasvir in an HCV+ gastro-resected patient'. Together they form a unique fingerprint.

Cite this